In the April–June 2015 edition of Corporate Disputes, Dr. Gregory Bell and Professor Iain Cockburn discuss damages in the pharmaceutical and biotech sector . To read more, click on the link below.
What is driving obesity market growth and what does that mean for manufacturers?
Are GLP-1 weight-loss therapies growing primarily by expanding the treatment population or by capturing share from existing obesity therapies? Obesity afflicts...
